BIOMAT Database Logo BIOMAT Database Logo

Penicillamine-induced myasthenia gravis. 1979

W R Sundstrom, and A A Schuna

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D010396 Penicillamine 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease. Dimethylcysteine,Mercaptovaline,beta,beta-Dimethylcysteine,Copper Penicillaminate,Cuprenil,Cuprimine,D-3-Mercaptovaline,D-Penicillamine,Metalcaptase,D 3 Mercaptovaline,D Penicillamine,Penicillaminate, Copper,beta,beta Dimethylcysteine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis

Related Publications

W R Sundstrom, and A A Schuna
[Penicillamine-induced myasthenia gravis].
September 1983, Deutsche medizinische Wochenschrift (1946),
W R Sundstrom, and A A Schuna
[Penicillamine-induced myasthenia gravis].
January 2001, Ryoikibetsu shokogun shirizu,
W R Sundstrom, and A A Schuna
Penicillamine-induced myasthenia gravis.
February 1984, Journal of the Mississippi State Medical Association,
W R Sundstrom, and A A Schuna
[Penicillamine induced myasthenia gravis].
July 1980, Ugeskrift for laeger,
W R Sundstrom, and A A Schuna
D-Penicillamine induced myasthenia gravis.
October 2002, Neurosciences (Riyadh, Saudi Arabia),
W R Sundstrom, and A A Schuna
[D-penicillamine-induced myasthenia gravis].
January 1984, Duodecim; laaketieteellinen aikakauskirja,
W R Sundstrom, and A A Schuna
Penicillamine-induced ocular myasthenia gravis.
January 1985, American journal of ophthalmology,
W R Sundstrom, and A A Schuna
[D-penicillamine-induced myasthenia gravis].
May 1994, Schweizerische medizinische Wochenschrift,
W R Sundstrom, and A A Schuna
[Myasthenia gravis induced by D-penicillamine].
August 1983, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
W R Sundstrom, and A A Schuna
The pathophysiology of penicillamine-induced myasthenia gravis.
December 1986, Annals of neurology,
Copied contents to your clipboard!